Russell Investments Group, Ltd. Immuno Gen, Inc. Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$12.46 - $29.95 $30,639 - $73,647	-2,459 Reduced 13.98%	15,134 $448,000
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $36,732 - $51,801	2,607 Added 17.4%	17,593 $279,000
Q2 2023 Aug 10, 2023	SELL	$3.75 - $20.05 $111,802 - $597,770	-29,814 Reduced 66.55%	14,986 $282,000
Q1 2023 May 09, 2023	SELL	$3.67 - $4.92 $27,158 - $36,408	-7,400 Reduced 14.18%	44,800 $172,000
Q4 2022 Feb 08, 2023	BUY	$4.55 - $6.31 $169,715 - $235,362	37,300 Added 250.34%	52,200 $258,000
Q1 2021 May 10, 2021	SELL	$6.5 - $10.53 $637,773 - $1.03 Million	-98,119 Reduced 86.82%	14,900 $120,000
Q4 2020 Feb 08, 2021	SELL	$3.7 - $7.66 $19,502 - $40,375	-5,271 Reduced 4.46%	113,019 $728,000
Q3 2020 Nov 09, 2020	BUY	$3.45 - $4.89 $158,624 - $224,832	45,978 Added 63.58%	118,290 $424,000
Q2 2020 Aug 05, 2020	SELL	$3.32 - $5.34 $264,355 - $425,197	-79,625 Reduced 52.41%	72,312 $329,000
Q1 2020 May 06, 2020	BUY	$2.12 - $6.8 $169,254 - $542,891	79,837 Added 110.73%	151,937 $519,000
Q4 2019 Jan 29, 2020	BUY	$2.25 - $5.8 $160,200 - $412,960	71,200 Added 7911.11%	72,100 $368,000
Q3 2019 Nov 01, 2019	BUY	$2.22 - $3.39 $1,998 - $3,051	900 New	900 $2,000
Q3 2018 Oct 26, 2018	SELL	$8.6 - $11.26 $1.25 Million - $1.63 Million	-145,115 Closed	0 $0
Q2 2018 Aug 08, 2018	SELL	$9.52 - $12.15 $119,542 - $152,567	-12,557 Reduced 7.96%	145,115 $1.41 Million
Q1 2018 May 11, 2018	BUY	$6.7 - $12.95 $359,414 - $694,689	53,644 Added 51.57%	157,672 $1.66 Million
Q4 2017 Feb 06, 2018	BUY	$5.07 - $7.92 $41,107 - $64,215	8,108 Added 8.45%	104,028 $695,000
Q3 2017 Nov 07, 2017	BUY	$5.4 - $8.47 $517,968 - $812,442	95,920	95,920 $734,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account